The short version of Selank fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-05. Anything still debated is marked as such rather than presented as settled.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic heptapeptide | Stabilized analog of tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form: TKPRPGP |
| Molecular formula | C33H57N11O9 | Monoisotopic mass about 751.9 Da |
| Appearance | White to off-white powder | Typically supplied as lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in common polar solvents |
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
== Subcellular distribution == The peptide recognition domain of epiplakin is able to bind to keratins in vitro; however, in cells the epiplakin associates with keratin intermediate filaments networks only under conditions in which cellular stress is absent. Otherwise, epiplakin remains universally cytoplasmic and not bound to the intermediate filaments.
Many of the following substances have been referred to as vitamins as they were once believed to be vitamins. They are no longer considered as such, and the numbers that were assigned to them now form the "gaps" in the true series of B-complex vitamins described above (for example, there is no vitamin B4). Some of them, though not essential to humans, are essential in the diets of other organisms; others have no known nutritional value and may even be toxic under certain conditions.
Radiofrequency ablation of sensory knee nerves, also called genicular neurotomy or genicular RFA, is an outpatient procedure used to reduce pain from knee osteoarthritis. In the procedure for genicular RFA, a guide cannula is first directed under local anesthesia and imaging (ultrasound or fluoroscopy) to each target genicular nerve, then the radiofrequency electrode is passed through the cannula, and the electrode tip is heated to about 80 °C (176 °F) for one minute to cauterize a small segment of the nerve. The heat destroys that segment of the nerve, which is prevented from sending pain signals to the brain. As of 2023, reviews of clinical outcomes indicated that efficacy for reducing knee pain was achieved by ablating three or more branches of the genicular nerve (one of the articular branches of the tibial nerve). Other sources indicate 4–5 genicular nerve targets may be justified for ablation to optimize pain relief, while a 2022 analysis indicated that as many as 10 genicular nerve targets for RFA would produce better long-term relief of knee pain. Knee pain relief of 50% or more following genicular RFA may last from several months to two years, and can be repeated by the same outpatient procedure when pain recurs. Injection of phenol may be used as a neurolytic treatment of sensory knee nerves to relieve chronic pain from knee osteoarthritis.
Sources: en.wikipedia.org
=== 18 January === Forty people were killed in an RSF attack on the village of Jebel Hilla in North Darfur. Six drones struck the Al-Shawak power station in Gedaref State, injuring civil defence personnel and causing blackouts across the state and in Kassala State. Other drones hit the Gedaref state water station while another crashed near a bus station along the Gedaref-Kassala-Port Sudan highway. The SAF reached the Al-Shukri junction in Shambat, Khartoum Bahri, while the RSF retreated by one kilometer southwards to the Hassan Ibrahim Malik University City. At least three people were killed by RSF shelling in Omdurman. The RSF claimed to have taken Al-Hallaf, Drishaqi and Mao in North Darfur.
Center for Medicare (CM) Center for Medicaid and CHIP Services (CMCS) Center for Medicare and Medicaid Innovation (CMMI, a.k.a. the CMS Innovation Center) Center for Consumer Information and Insurance Oversight (CCIIO) Center for Program Integrity (CPI) Center for Clinical Standards and Quality (CCSQ) The regions:
Cyanobactins are diverse metabolites from cyanobacteria with N-to-C macrocylization of a 6–20 amino acid chain. Cyanobactins are natural products isolated from cyanobacteria, and close to 30% of all cyanobacterial strains are thought to contain cyanobacterial gene clusters. However, while thus far all cyanobactins are credited to cyanobacteria, there exists the possibility that other organisms could produce similar natural products. The precursor peptide of the cyanobactin family is traditionally designated the "E" gene, whereas precursor peptides are designated gene "A" in most RiPP gene clusters. "A" is a serine protease involved in cleavage of the leader peptide and subsequent macrocyclization of the peptide natural product, in combination with an additional serine protease homologue, the encoded by gene "G". Members of the cyanobactin family may bear thiazolines/oxazolines, thiazoles/oxazoles, and methylations depending on additional modification enzymes. For example, perhaps the most famous cyanobactin is patellamide A, which contains two thiazoles, a methyloxazoline, and an oxazoline in its final state, a macrocycle derived from 8 amino acids.
While the body can synthesize it, it is also obtained from the diet and produced industrially by chemical synthesis for use as a food additive, a nutritional supplement, and an intermediate in the manufacture of products such as the herbicide glyphosate. Glycine can fit into hydrophobic environments due to its minimal side chain.
Sources: en.wikipedia.org
At the beginning of the 3rd century BCE the cities of southern Italy, which had been allies of the Samnites, were still independent, but inevitably came into conflict as a result of Rome's expansion as their expansion in central and northern Italy was not sufficient to provide arable lands they needed.
=== Australia === From 2023, Juniper was cited in multiple reports examining the regulation of telehealth-based weight-loss services in Australia. The Royal Australian College of General Practitioners (RACGP) and medical regulators raised concerns about prescribing models relying on asynchronous or questionnaire-based assessments for injectable weight-loss medications. The TGA assessed whether online advertising by Juniper (and its competitors) could indirectly promote prescription-only medicines in breach of federal law. Between 2022 and 2024 they requested the removal of thousands of unlawful advertisements. In response to updated guidance from the Medical Board of Australia (MBA) restricting "tick-and-flick" prescribing, Eucalyptus Health said that its platforms would comply with requirements for real-time clinical consultation and enhanced verification. In July 2023, the TGA opened an investigation into whether email communications sent by Juniper to people on its contact list about the availability of Ozempic constituted unlawful advertising. Through 2024, the TGA proposed the removal of GLP-1 medicines from pharmacy compounding exemptions due to concerns that telehealth prescribing models were inconsistent with exemptions intended for individual patient use. They warned that compounded GLP-1 products were not subject to the same safety, quality, or adverse-event reporting requirements as TGA-approved medicines. Juniper was one of the companies prescribing them.
=== Category:EC 1.3 (act on the CH-CH group of donors) === Category:EC 1.3.1 (with NAD+ or NADP+ as acceptor) Biliverdin reductase EC 1.3.1.24 Category:EC 1.3.2 (with a cytochrome as acceptor) Category:EC 1.3.3 (with oxygen as acceptor) Protoporphyrinogen oxidase EC 1.3.3.4 Category:EC 1.3.5 (with a quinone or similar compound as acceptor) Category:EC 1.3.7 (with an iron–sulfur protein as acceptor) Category:EC 1.3.99 (with other acceptors)
Sources: en.wikipedia.org
Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.
It was developed in Russia, at the Institute of Molecular Genetics of the Russian Academy of Sciences, during the 1990s. Most published research originates from Russian institutions. Independent international replication remains limited.
Tuftsin is a natural tetrapeptide with the sequence Thr-Lys-Pro-Arg that participates in immune signaling. Selank extends that sequence with Pro-Gly-Pro at the C-terminus. The added residues are linked to greater resistance to enzymatic breakdown.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.